Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed) | PAR 19 194

Frequently Asked Questions (FAQs)

What is the official title of this NIH funding opportunity?

The funding opportunity is titled "Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)" with FOA number PAR-19-194.

What is the main goal of this FOA?

The main goal is to jump-start early-stage, high-impact research that uses microorganisms as anticancer therapies, especially for cancer situations where standard treatments often do not work well. The FOA aims to strengthen the scientific and preclinical foundation for "microbe-as-therapy" approaches.

What kinds of cancer settings is NIH especially interested in?

The FOA highlights difficult-to-treat contexts, including poorly vascularized and hypoxic solid tumors, tumor regions that are hard for drugs to reach, dormant or slow-cycling cancer cells that resist therapies targeting rapidly dividing cells, and brain tumors where delivery barriers and the tumor microenvironment can limit current options.

What does "Bugs as Drugs" mean in this program?

In this program, "Bugs as Drugs" refers to using non-viral microorganisms as the therapeutic agent itself or as a key part of a therapeutic strategy against cancer, either acting directly on tumors or working alongside existing therapies to improve outcomes.

Which microorganisms are within scope for this opportunity?

The FOA focuses on non-viral microorganisms, including bacteria, archaebacteria, bacteriophages, and other non-virus microbes.

Is this FOA about viruses or viral vectors?

The description emphasizes non-viral microorganisms (for example, bacteria and bacteriophages). The stated focus is on non-virus microbes rather than viral approaches.

Are clinical trials allowed under this funding opportunity?

No. The FOA is designated "Clinical Trial Not Allowed," and the scope is limited to basic mechanistic studies and preclinical work in cell culture and animal models.

What types of studies are supported (basic, translational, clinical)?

The supported scope is basic mechanistic and preclinical research, including studies in cell culture and animal models. The intent is to generate convincing mechanistic insight and preclinical evidence to support future translational steps, but not to conduct clinical trials under this FOA.

What does NIH mean by a "three-way relationship" among microbe, tumor, and immune system?

NIH is looking for projects that examine the interconnected interactions among the microorganism, the tumor, and the immune system. Proposals are expected to go beyond treating the microbe as a simple tool and instead study how microbial behavior, tumor biology, and immune responses shape each other and affect outcomes.

What kinds of mechanisms does NIH want applicants to investigate?

Examples called out include how microbes localize to tumors (including hypoxic regions), how microbes survive or are cleared, which immune pathways are activated or suppressed, and how immune changes influence tumor growth or tumor immune evasion.

Can microorganisms be used as delivery vehicles in this FOA?

Yes. A major theme is using microorganisms as delivery vehicles for cancer treatment, including engineering or selecting microbes to carry therapeutic payloads, express anticancer molecules in the tumor microenvironment, or concentrate treatment at tumor sites to reduce systemic toxicity.

Does the FOA encourage combining microbial therapies with existing cancer treatments?

Yes. The FOA explicitly encourages approaches that complement or synergize with established therapies such as chemotherapy, radiotherapy, immunotherapies, or other modalities, as long as the work remains basic mechanistic or preclinical.

What is meant by advancing the "preclinical development pipeline"?

It means generating mechanistic understanding and preclinical evidence (for example, in animal or cell culture models) that supports future translational development of microbial-based anticancer agents.

What kinds of project styles does the FOA consider appropriate?

The FOA indicates that projects may be hypothesis-driven, discovery-driven, design-directed, or developmental, as long as they are state-of-the-art and meaningfully advance knowledge or development readiness in microbial-based cancer therapy.

What is a key scientific expectation for strong applications?

Strong applications are expected to be integrative, linking microbial genetics or physiology, tumor microenvironment features, and immune mechanisms to explain not only whether a strategy works, but also why it works and under what conditions it may fail.

Do applicants need to address both the microbial and tumor components?

Yes. A key requirement is that proposed projects must address both the microbial component and the tumor component. NIH signals that applications should not focus only on microbial engineering without a serious tumor biology plan, and should not be purely tumor immunology without a substantive microbial therapeutic angle.

Is multidisciplinary collaboration important for this FOA?

Yes. Because the scientific questions span multiple domains, the FOA emphasizes multidisciplinary collaboration and encourages teams combining expertise such as microbiology, oncology, immunology, and cellular and molecular cancer biology.

What funding mechanism is used for this opportunity?

This opportunity uses the NIH R21 mechanism, which is commonly used for exploratory, early-stage projects intended to prove feasibility or generate compelling preliminary data.

What is the award ceiling mentioned in the opportunity description?

The listed award ceiling is $200,000.

Which agency is offering this funding opportunity?

The agency is the National Institutes of Health (NIH).

What CFDA numbers are associated with this program?

The program is associated with CFDA numbers 93.395 and 93.396.

Who is eligible to apply?

Eligibility is broad and includes many organization types, such as state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses) as well as small businesses; and additional categories described in the FOA.

Are minority-serving institutions and community-based organizations eligible?

Yes. The FOA highlights additional eligible applicant groups including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, AANAPISIs, and faith-based or community-based organizations.

Are non-US (foreign) entities eligible to apply?

Yes. The FOA explicitly includes non-US (foreign) entities among eligible applicants.

Are US territories or possessions included as eligible applicants?

Yes. The FOA includes US territories or possessions among the highlighted eligible applicant groups.

Is this opportunity intended to support late-stage development or immediate clinical translation?

No. Based on the stated scope and the "Clinical Trial Not Allowed" designation, the FOA is intended to support basic mechanistic and preclinical research rather than clinical testing.

What is the overall takeaway for applicants considering this FOA?

The opportunity is designed to fund innovative, multidisciplinary preclinical research that clarifies mechanisms, demonstrates promise in relevant models, and explains how microbial therapies could be developed to reach and treat tumors that are poorly served by conventional approaches.